SPOTLIGHT -
Fernando Dangond, MD, MBA: Phase 2 Data on Evobrutinib in MS
Head of Global Clinical Development in Neurology at EMD Serono discussed the findings of a phase 2 assessment of the company’s investigational BTK inhibitor evobrutinib in multiple sclerosis.
Fernando Dangond, MD, MBA: Evobrutinib for Relapsing Multiple Sclerosis
The Head of Global Clinical Development in Neurology at EMD Serono provided insight into the therapy's performance in phase IIb.
